ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Provided By PR Newswire
Last update: Sep 24, 2025
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms
Read more at prnewswire.com
